Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia.

Published in: Journal of psychopharmacology (Oxford, England) (2021)

Our results suggest that AIP is an easily calculable and reliable marker for determining the CVD risk in both drug-free schizophrenia patients and patients under AP treatment.

Keyphrases

cardiovascular disease
end stage renal disease
ejection fraction
bipolar disorder
prognostic factors
type diabetes
metabolic syndrome
coronary artery disease
transcription factor
smoking cessation